Reference data : LOINC code

Filter


Clear filter

Results
104,672 results found
Loinc Number Component Property System Time aspect ScaleType MethodType Relat_nms loincStatus Long Common name answerList chngType DefinitionDescription dtLastCh exactCmspy exampleUnits exmplAnswers externalCopyrightNotice formula hl7FieldSubfieldId InpcPercentage ipccUnits loincClass loincFinal loincNum mapTo methodTyp molarMass naaccrId orderObs panelElements reference scope setRoot shortName source surveyQuestSrc surveyQuestText unitsRequired acssym relatedNames2 VersionLastChanged VersionFirstRelease ValidHL7AttachmentRequest PanelType AssociatedObservations EXTERNAL_COPYRIGHT_LINK HL7_ATTACHMENT_STRUCTURE CONSUMER_NAME EXAMPLE_UCUM_UNITS STATUS_REASON STATUS_TEXT CHANGE_REASON_PUBLIC COMMON_TEST_RANK COMMON_ORDER_RANK
34057-0 Glucose^pre or post dose cloNIDine SCnc Ser/Plas Pt Qn     ACTIVE Glucose [Moles/volume] in Serum or Plasma --pre or post dose cloNIDine   MIN DefinitionDescription     mmol/L             CHAL   34057-0         Observation       0 Glucose pre/p CLN SerPl-sCnc       N   After; Before; Catapres; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; p dose; Pl; Plasma; Plsm; Point in time; pre/p CLN; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration 2.7 2.09               mmol/L       0
34058-8 Glucose^pre or post dose glucagon SCnc Ser/Plas Pt Qn     ACTIVE Glucose [Moles/volume] in Serum or Plasma --pre or post dose glucagon   MIN DefinitionDescription     mmol/L             CHAL   34058-8         Observation       0 Glucose pre/p Gc SerPl-sCnc       N   After; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HGF; Hyperglycemic factor; Level; p dose; Pl; Plasma; Plsm; Point in time; pre/p Gc; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration 2.7 2.09               mmol/L       0
34059-6 Glucose^pre or post dose glucose SCnc Ser/Plas Pt Qn     ACTIVE Glucose [Moles/volume] in Serum or Plasma --pre or post dose glucose   MIN DefinitionDescription     mmol/L             CHAL   34059-6         Observation       0 Glucose pre/p Glc SerPl-sCnc       N   After; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; p dose; p Glc; Pl; Plasma; Plsm; Point in time; pre/p Glc; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration 2.7 2.09               mmol/L       0
3406-6 Bromazepam MCnc Urine Pt Qn     ACTIVE Bromazepam [Mass/volume] in Urine   MIN DefinitionDescription     ng/mL             DRUG/TOX   3406-6         Both       0 Bromazepam Ur-mCnc       Y   Bromazanil; Brozam; Calmepam; Compendium; Creosedin; DRUG/TOXICOLOGY; Drugs; Durazanil; Gityl; Lectopam; Level; Lexatin; Lexaurin; Lexonil; Lexotan; Lexotanil; Mass concentration; Neo-opt; Normoc; Point in time; QNT; Quan; Quant; Quantitative; Random; Somalium; UA; UR; Urn 2.42 1               ng/mL       0
34060-4 Glucose^pre or post dose insulin SCnc Ser/Plas Pt Qn     ACTIVE Glucose [Moles/volume] in Serum or Plasma --pre or post dose insulin   MIN DefinitionDescription     mmol/L             CHAL   34060-4         Observation       0 Glucose pre/p Ins SerPl-sCnc       N   After; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HUM; Humulin; IH7; Insul; Lente; Level; NPH; p dose; Pl; Plasma; Plsm; Point in time; pre/p Ins; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Substance concentration; Ultralente 2.7 2.09               mmol/L       0
34061-2 Somatotropin^pre or post dose arginine MCnc Ser/Plas Pt Qn     ACTIVE Somatotropin [Mass/volume] in Serum or Plasma --pre or post dose arginine   MIN DefinitionDescription     ug/L;ng/mL             CHAL   34061-2         Observation       0 GH pre/p Arg SerPl-mCnc       N   After; Arg; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; pre/p Arg; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH 2.7 2.09               ng/mL       0
34062-0 Somatotropin^pre or post dose cloNIDine MCnc Ser/Plas Pt Qn     ACTIVE Somatotropin [Mass/volume] in Serum or Plasma --pre or post dose cloNIDine   MIN DefinitionDescription     ug/L;ng/mL             CHAL   34062-0         Observation       0 GH pre/p CLN SerPl-mCnc       N   After; Before; Catapres; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; pre/p CLN; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH 2.7 2.09               ng/mL       0
34063-8 Somatotropin^pre or post dose glucagon MCnc Ser/Plas Pt Qn     ACTIVE Somatotropin [Mass/volume] in Serum or Plasma --pre or post dose glucagon   MIN DefinitionDescription     ug/L;ng/mL             CHAL   34063-8         Observation       0 GH pre/p Gc SerPl-mCnc       N   After; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGF; HGH; Human growth hormone; Hyperglycemic factor; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; pre/p Gc; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH 2.7 2.09               ng/mL       0
34064-6 Somatotropin^pre or post dose insulin MCnc Ser/Plas Pt Qn     ACTIVE Somatotropin [Mass/volume] in Serum or Plasma --pre or post dose insulin   MIN DefinitionDescription     ug/L;ng/mL             CHAL   34064-6         Observation       0 GH pre/p Ins SerPl-mCnc       N   After; Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; HUM; Human growth hormone; Humulin; IH7; Insul; Lente; Level; Mass concentration; NPH; p dose; Pl; Plasma; Plsm; Point in time; pre/p Ins; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; Somatotropic hormone; SR; STH; Ultralente 2.7 2.09               ng/mL       0
34065-3 Cortisol^pre or post dose corticotropin SCnc Ser/Plas Pt Qn     ACTIVE Cortisol [Moles/volume] in Serum or Plasma --pre or post dose corticotropin   MIN DefinitionDescription     nmol/L             CHAL   34065-3         Observation       0 Cortis pre/p ACTH SerPl-sCnc       N   17-Hydroxycorticosterone; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; Before; c206; c74; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; Cortrosyn; F; hydrocortisone; Level; p ACTH; p dose; Pl; Plasma; Plsm; Point in time; pre/p ACTH; PST; QNT; Quan; Quant; Quantitative; Random; Rc206; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration; Tumor marker 2.7 2.09               nmol/L       0
34066-1 Boxed warning section - ^FDA package insert - Nar     ACTIVE FDA package insert Boxed warning section   MIN DefinitionDescription                   DOC.REF   34066-1                 0 FDA insert Boxed warning       N   DOCUMENT.REF; FDA insert; Narrative; Report; SPL; Structured Product Labelling 2.34 2.09                       0
34067-9 Indications & usage section - ^FDA package insert - Nar     ACTIVE FDA package insert Indications and usage section   MIN DefinitionDescription                   DOC.REF   34067-9                 0 FDA insert Indications/usage       N   DOCUMENT.REF; FDA insert; Indications/usage; Narrative; Report; SPL; Structured Product Labelling 2.38 2.09                       0
34068-7 Dosage & administration section - ^FDA package insert - Nar     ACTIVE FDA package insert Dosage and administration section   MIN DefinitionDescription                   DOC.REF   34068-7                 0 FDA insert Dose & admin       N   DOCUMENT.REF; Dose & admin; FDA insert; Narrative; Report; SPL; Structured Product Labelling 2.38 2.09                       0
34069-5 How supplied section - ^FDA package insert - Nar     ACTIVE FDA package insert How supplied section   MIN DefinitionDescription                   DOC.REF   34069-5                 0 FDA insert How supplied       N   DOCUMENT.REF; FDA insert; Narrative; Report; SPL; Structured Product Labelling 2.34 2.09                       0
3407-4 Brompheniramine PrThr Ser/Plas Pt Ord     ACTIVE Brompheniramine [Presence] in Serum or Plasma   MIN DefinitionDescription                   DRUG/TOX   3407-4         Both       0 Brompheniramine SerPl Ql           Antial; BPN; Bromarest; Bromfed; Bromfenex; Dimegan; Dimetane; Dimetapp; Dimotane; DRUG/TOXICOLOGY; Drugs; Gammistin; Ilvin; Lodrane; Ordinal; Parabromdylamine maleate; Pl; Plasma; Plsm; Point in time; PR; PROBAHIST; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR 2.56 1                     The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. 0
34070-3 Contraindications section - ^FDA package insert - Nar     ACTIVE FDA package insert Contraindications section   MIN DefinitionDescription                   DOC.REF   34070-3                 0 FDA insert Contraindications       N   DOCUMENT.REF; FDA insert; Narrative; Report; SPL; Structured Product Labelling 2.34 2.09                       0
34071-1 Warnings section - ^FDA package insert - Nar     ACTIVE FDA package insert Warnings section   MIN DefinitionDescription                   DOC.REF   34071-1                 0 FDA insert Warnings       N   DOCUMENT.REF; FDA insert; Narrative; Report; SPL; Structured Product Labelling 2.34 2.09                       0
34072-9 General precautions section - ^FDA package insert - Nar     ACTIVE FDA package insert General precautions section   MIN DefinitionDescription                   DOC.REF   34072-9                 0 FDA insert General precautions       N   DOCUMENT.REF; FDA insert; Narrative; Report; SPL; Structured Product Labelling 2.34 2.09                       0
34073-7 Drug interactions section - ^FDA package insert - Nar     ACTIVE FDA package insert Drug interactions section   MIN DefinitionDescription                   DOC.REF   34073-7                 0 FDA insert Drug interactions       N   DOCUMENT.REF; Drugs; FDA insert; Narrative; Report; SPL; Structured Product Labelling 2.34 2.09                       0
34074-5 Drug &or laboratory test interactions section - ^FDA package insert - Nar     ACTIVE FDA package insert Drug/laboratory test interactions section   MIN DefinitionDescription                   DOC.REF   34074-5                 0 FDA insert Drug/lab test interactions       N   DOCUMENT.REF; Drug/lab test interactions; Drugs; FDA insert; Narrative; Report; SPL; Structured Product Labelling 2.34 2.09                       0
34075-2 Laboratory tests section - ^FDA package insert - Nar     ACTIVE FDA package insert Laboratory tests section   MIN DefinitionDescription                   DOC.REF   34075-2                 0 FDA insert Lab tests       N   DOCUMENT.REF; FDA insert; Lab tests; Narrative; Report; SPL; Structured Product Labelling 2.34 2.09                       0
34076-0 Information for patients section - ^FDA package insert - Nar     ACTIVE FDA package insert Information for patients section   MIN DefinitionDescription                   DOC.REF   34076-0                 0 FDA insert Info for patients       N   DOCUMENT.REF; FDA insert; Info for patients; Narrative; Report; SPL; Structured Product Labelling 2.34 2.09                       0
34077-8 Teratogenic effects section - ^FDA package insert - Nar     ACTIVE FDA package insert Teratogenic effects section   MIN DefinitionDescription                   DOC.REF   34077-8                 0 FDA insert Teratogenic effects       N   DOCUMENT.REF; FDA insert; Narrative; Report; SPL; Structured Product Labelling 2.34 2.09                       0
34078-6 Nonteratogenic effects section - ^FDA package insert - Nar     ACTIVE FDA package insert Nonteratogenic effects section   MIN DefinitionDescription                   DOC.REF   34078-6                 0 FDA insert Nonteratogenic effects       N   DOCUMENT.REF; FDA insert; Narrative; Report; SPL; Structured Product Labelling 2.34 2.09                       0
34079-4 Labor & delivery section - ^FDA package insert - Nar     ACTIVE FDA package insert Labor and delivery section   MIN DefinitionDescription                   DOC.REF   34079-4                 0 FDA insert Labor & delivery       N   DOCUMENT.REF; FDA insert; Narrative; Report; SPL; Structured Product Labelling 2.38 2.09                       0
104,672 results found